Russia's First Biological Chip for Alzheimer Risk

Russia has launched its first locally developed biological chip to assess the genetic risk of developing Alzheimer's disease, called "BioChip-A." It has been tested on 216 patients in Moscow. The chip is a registered medical device that allows doctors to determine the likelihood of developing the disease based on genetic patterns. It is used as part of a comprehensive patient evaluation alongside clinical data but does not provide a direct diagnosis. The development aims to improve early detection of genetic risks associated with the disease. Currently, it is employed as part of the clinical trial phase, with financial support from the Moscow Mayor’s grant program.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل